NVCR | NovoCure Limited Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	25.10 - 25.75
52 Week Range	11.70 - 34.13
Beta	0.78
Implied Volatility	49.92%
IV Rank	2.33%
Day's Volume	536,070
Average Volume	1,247,640
Shares Outstanding	108,201,000
Market Cap	2,761,289,520
Sector	Healthcare
Industry	Medical - Instruments & Supplies
IPO Date	2015-10-01

Valuation
Profitability
Growth
Health
P/E Ratio	-18.36
Forward P/E Ratio	N/A
EPS	-1.39
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	1,453
Country	Jersey
Website	NVCR

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

NVCR's peers: AXON, BIO, GMED, INSP, NNOX, PODD, NARI, TMDX, INMD, ITGR, CNMD, LIVN, IRTC, HSKA, SWAV, PEN, MASI, PHG

*Chart delayed

Analyzing fundamentals for NVCR we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is exceptionally good and Health is frighteningly weak. For more detailed analysis please see NVCR Fundamentals page.

Watching at NVCR technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on NVCR Technicals page.